GO:0006635 fatty acid beta-oxidation: Mitochondrial Energy Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006635 fatty acid beta-oxidation is the biological process that breaks down fatty acyl chains into acetyl-CoA, generating reducing equivalents for ATP production.
• Mitochondrial beta-oxidation is the dominant energy-supplying pathway in heart, liver, and skeletal muscle, and its dysfunction causes inherited metabolic disease.
• The pathway is regulated by nutrient sensors and transcription factors including SIRT1, PGC-1alpha, and PPARalpha.
• Fatty acid transport proteins such as FABP5 and CD36 deliver substrates and also act as signaling molecules that modulate beta-oxidation.
• Stress granules and neuron-astrocyte metabolic coupling can acutely inhibit or protect against fatty acid oxidation, linking the pathway to stress responses and neurodegeneration.
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models enable causal dissection of beta-oxidation genes in metabolic and cardiovascular disease.
Description
GO:0006635 fatty acid beta-oxidation is a central catabolic biological process in which fatty acyl chains are oxidatively cleaved to produce acetyl-CoA, NADH, and FADH2, which feed the tricarboxylic acid cycle and oxidative phosphorylation. The pathway is essential for energy homeostasis, particularly in tissues with high ATP demand such as the heart, liver, and skeletal muscle. In mitochondria, beta-oxidation is coupled to the electron transport chain, and its flux is dynamically matched to nutrient availability and hormonal signals. Beyond energy production, beta-oxidation intermediates participate in signaling and metabolic crosstalk, and impaired flux is a hallmark of inherited fatty acid oxidation disorders and acquired metabolic diseases. Understanding the genes, regulation, and disease links of GO:0006635 is therefore a priority for metabolic, cardiovascular, and neuroscience researchers.
fatty acid beta-oxidation At A Glance
| GO ID | GO:0006635 |
|---|---|
| GO term | fatty acid beta-oxidation |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Oxidative catabolism of fatty acyl chains to acetyl-CoA, NADH, and FADH2 for energy production |
| Subcellular location | Mitochondrial matrix (primary site in mammals) |
| Key substrates | Acyl-CoA esters of varying chain length |
| Key cofactors | FAD, NAD+, carnitine, coenzyme A |
| Regulatory nodes | SIRT1/PGC-1alpha/PPARalpha, FABP5, stress granules |
| Disease relevance | Inherited fatty acid oxidation disorders, MASLD, cardiac disease, neurodegeneration |
What Is GO:0006635?
Fatty acid beta-oxidation (GO:0006635) is the biological process in which fatty acids are catabolized by iterative cycles of dehydrogenation, hydration, dehydrogenation, and thiolytic cleavage, removing two-carbon units as acetyl-CoA. In mitochondria, this process requires activation of fatty acids to acyl-CoA, carnitine-dependent transport into the matrix, and a set of chain-length-specific enzymes. The process is a major source of reducing equivalents for ATP synthesis and is tightly regulated by substrate supply, hormonal signals, and transcriptional programs.
Why Is fatty acid beta-oxidation Important in Cell Biology?
GO:0006635 fatty acid beta-oxidation is indispensable for whole-body energy homeostasis because it supplies the majority of ATP in heart and skeletal muscle during fasting and exercise, and its failure causes hypoglycemia, cardiomyopathy, and sudden death in inherited disorders. The pathway is also a therapeutic target in metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure, where modulating beta-oxidation flux can improve lipid handling and reduce lipotoxicity. In the brain, beta-oxidation and fatty acid trafficking are implicated in activity-induced fatty acid toxicity and neuron-astrocyte metabolic coupling, linking the process to neurodegeneration. Because beta-oxidation is regulated by nutrient sensors and stress pathways, it sits at the intersection of metabolism, signaling, and disease.
• Supplies acetyl-CoA for the TCA cycle and ATP production in heart, liver, and skeletal muscle.
• Maintains energy homeostasis during fasting and prolonged exercise.
• Dysfunction causes inherited fatty acid oxidation disorders with cardiomyopathy and hypoglycemia.
• Modulating beta-oxidation is a therapeutic strategy in MASLD and steatohepatitis.
• Fatty acid transport and signaling proteins such as FABP5 and CD36 regulate beta-oxidation flux.
• Stress granules can acutely inhibit fatty acid oxidation by modulating mitochondrial permeability.
• Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity.
• Beta-oxidation is a target of SIRT1/PGC-1alpha/PPARalpha signaling in metabolic disease.
• The pathway is relevant to cardiac energy metabolism in health and disease.
• CRISPR models enable causal testing of beta-oxidation genes in metabolic phenotypes.
What Happens During fatty acid beta-oxidation?
Fatty acid activation and carnitine-dependent transport
In simple terms: Fatty acids must be switched on and carried into the mitochondria before they can be burned.
Long-chain fatty acids are activated to acyl-CoA by acyl-CoA synthetases and then converted to acylcarnitines by carnitine palmitoyltransferase 1 (CPT1) for transport across the mitochondrial membrane. Carnitine palmitoyltransferase 2 (CPT2) and the carnitine-acylcarnitine translocase (CACT) complete the shuttle into the matrix, where beta-oxidation enzymes reside. This transport step is rate-limiting and is a major regulatory node of GO:0006635.
The four-step beta-oxidation spiral
In simple terms: Each round of beta-oxidation shortens the fatty acid by two carbons and produces energy-carrying molecules.
The core spiral consists of acyl-CoA dehydrogenase (dehydrogenation), enoyl-CoA hydratase (hydration), 3-hydroxyacyl-CoA dehydrogenase (second dehydrogenation), and 3-ketoacyl-CoA thiolase (thiolytic cleavage). Each cycle removes one acetyl-CoA and generates one FADH2 and one NADH, which feed oxidative phosphorylation. Chain-length-specific isoenzymes handle short, medium, long, and very-long-chain substrates.
Acetyl-CoA oxidation and ATP generation
In simple terms: The acetyl-CoA produced by beta-oxidation enters the TCA cycle to make ATP.
Acetyl-CoA generated by beta-oxidation is oxidized in the tricarboxylic acid cycle, producing NADH and FADH2 that drive mitochondrial ATP synthesis. In the heart, fatty acid oxidation provides the majority of ATP under normal conditions, and flux is dynamically matched to workload. This coupling explains why defects in beta-oxidation rapidly impair high-energy-demand tissues.
Regulation by nutrient sensors and transcription factors
In simple terms: The cell adjusts how much fat it burns based on nutrient signals and gene expression programs.
The SIRT1/PGC-1alpha/PPARalpha axis promotes fatty acid beta-oxidation gene expression and is a therapeutic target in steatohepatitis. FABP5 interacts with asprosin to modulate mitochondrial fatty acid oxidation through PPARalpha in MASLD. Fatty acid transport and signaling mechanisms further tune substrate delivery and pathway flux.
Acute inhibition by stress and metabolic coupling
In simple terms: Stress and cell-to-cell communication can quickly turn down fat burning.
Stress granules inhibit fatty acid oxidation by modulating mitochondrial permeability, linking cellular stress to metabolic suppression. Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity, indicating that beta-oxidation is regulated by intercellular metabolic interactions. These mechanisms highlight that GO:0006635 is not a static pathway but a dynamically controlled process.
Key Genes Involved in GO:0006635 fatty acid beta-oxidation
The following genes and proteins are core components, regulators, or transporters of GO:0006635 fatty acid beta-oxidation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CPT1A | Rate-limiting carnitine palmitoyltransferase for mitochondrial fatty acid import | Target for modulating beta-oxidation flux in metabolic disease |
| CPT2 | Inner membrane carnitine palmitoyltransferase completing acyl-carnitine shuttle | Defects cause inherited fatty acid oxidation disorders |
| SLC25A20 | Carnitine-acylcarnitine translocase (CACT) for acylcarnitine transport | Loss-of-function causes neonatal metabolic crisis |
| ACADVL | Very-long-chain acyl-CoA dehydrogenase, first step of beta-oxidation | Deficiency causes cardiomyopathy and hypoglycemia |
| ACADM | Medium-chain acyl-CoA dehydrogenase | MCAD deficiency is a common inherited fatty acid oxidation disorder |
| ACADS | Short-chain acyl-CoA dehydrogenase | Associated with metabolic decompensation |
| HADHA | Long-chain 3-hydroxyacyl-CoA dehydrogenase subunit | Deficiency causes LCHAD deficiency with cardiomyopathy |
| HADHB | Long-chain 3-ketoacyl-CoA thiolase subunit | Deficiency causes mitochondrial trifunctional protein deficiency |
| ACAA2 | Mitochondrial 3-ketoacyl-CoA thiolase | Contributes to acetyl-CoA generation from beta-oxidation |
| PPARA | Nuclear receptor driving beta-oxidation gene expression | Therapeutic target in MASLD and steatohepatitis |
| PPARGC1A | PGC-1alpha coactivator of PPARalpha and mitochondrial biogenesis | Regulates oxidative metabolism and beta-oxidation capacity |
| SIRT1 | NAD+-dependent deacetylase upstream of PGC-1alpha/PPARalpha | Modulates beta-oxidation in steatohepatitis models |
| FABP5 | Fatty acid binding protein mediating asprosin signaling to PPARalpha | Modulates mitochondrial fatty acid oxidation in MASLD |
| CD36 | Fatty acid transport protein and signaling receptor | Regulates substrate delivery for beta-oxidation |
| FABP3 | Heart-type fatty acid binding protein | Relevant to myocardial fatty acid metabolism |
| ACSL1 | Acyl-CoA synthetase activating long-chain fatty acids | Required for substrate entry into beta-oxidation |
| ETFA | Electron transfer flavoprotein subunit for acyl-CoA dehydrogenases | Defects cause glutaric acidemia type II |
| ETFB | Electron transfer flavoprotein subunit | Supports electron transfer from beta-oxidation to respiratory chain |
How Is fatty acid beta-oxidation Regulated?
GO:0006635 fatty acid beta-oxidation is regulated at multiple levels. Transcriptional control is mediated by the SIRT1/PGC-1alpha/PPARalpha axis, which promotes expression of beta-oxidation enzymes and mitochondrial biogenesis. Substrate delivery and signaling are modulated by fatty acid transport proteins such as FABP5 and CD36, which can influence PPARalpha activity and pathway flux. Acute regulation occurs through stress-responsive mechanisms: stress granules inhibit fatty acid oxidation by modulating mitochondrial permeability, and neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. In the heart, beta-oxidation flux is matched to workload and substrate availability, and its dysregulation contributes to cardiac disease.
fatty acid beta-oxidation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACADM | Medium-chain acyl-CoA dehydrogenase deficiency with hypoglycemia | Knockout HepG2 or primary hepatocytes for flux analysis |
| HADHA | Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency with cardiomyopathy | Patient-derived fibroblasts and CRISPR-corrected isogenic lines |
| CPT2 | Inherited carnitine palmitoyltransferase II deficiency with rhabdomyolysis | Knockout myotubes and acylcarnitine profiling |
| PPARA | MASLD and steatohepatitis | Overexpression and knockout hepatocyte models with PPARalpha agonists |
| FABP5 | MASLD via asprosin-PPARalpha signaling | Knockout and knock-in hepatocytes for lipid flux assays |
Inherited fatty acid oxidation disorders
Mutations in genes encoding beta-oxidation enzymes and transport proteins cause inherited disorders that can present with hypoglycemia, cardiomyopathy, rhabdomyolysis, and sudden death. Deficiencies of CPT2, ACADVL, ACADM, HADHA, and HADHB are well-characterized examples, and newborn screening and acylcarnitine profiling are used for diagnosis. These disorders directly demonstrate the non-redundant role of GO:0006635 in human energy metabolism.
Metabolic dysfunction-associated steatotic liver disease (MASLD)
Impaired or insufficient fatty acid beta-oxidation contributes to hepatic lipid accumulation and steatohepatitis. Activation of the SIRT1/PGC-1alpha/PPARalpha pathway by formononetin promotes beta-oxidation and treats non-alcoholic steatohepatitis in preclinical models. Asprosin-FABP5 interaction modulates mitochondrial fatty acid oxidation through PPARalpha and contributes to MASLD development. These findings identify beta-oxidation as a therapeutic node in fatty liver disease.
Cardiac disease
The heart relies heavily on fatty acid beta-oxidation for ATP production, and alterations in this pathway are implicated in heart failure and ischemic injury. Myocardial fatty acid metabolism is dynamically regulated in health and disease, and therapeutic strategies targeting substrate selection are under investigation. Defects in beta-oxidation genes also cause cardiomyopathy as part of inherited disorders.
Neurodegeneration and fatty acid toxicity
Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity, suggesting that dysregulated fatty acid handling contributes to neuronal stress. Stress granules inhibit fatty acid oxidation by modulating mitochondrial permeability, linking stress responses to metabolic dysfunction in neurons. These mechanisms connect GO:0006635 to neurodegeneration and brain energy metabolism.
From fatty acid beta-oxidation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a beta-oxidation gene required for fatty acid flux? | CRISPR knockout in HepG2, Huh7, or primary hepatocytes |
| Does a patient variant impair enzyme function? | Point-mutation knock-in of the variant in an isogenic cell line |
| Does a regulatory element control PPARA or beta-oxidation genes? | Knock-in of reporter or degron tags at the endogenous locus |
| Does overexpression of a regulator increase beta-oxidation? | Overexpression of SIRT1, PGC-1alpha, or PPARalpha in hepatocytes |
| Does a transport protein modulate substrate delivery? | Knockout or overexpression of FABP5 or CD36 in metabolic cell models |
| Does stress signaling inhibit beta-oxidation? | Stress-granule induction in neuronal or hepatic cells with flux readouts |
How to Study the fatty acid beta-oxidation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Acylcarnitine profiling by mass spectrometry | Accumulation of beta-oxidation intermediates | Diagnosis of inherited fatty acid oxidation disorders |
| Radiolabeled fatty acid oxidation assay | Flux through beta-oxidation | Functional validation of gene knockouts |
| RNA-seq | Expression of beta-oxidation genes and regulators | Testing PPARalpha pathway activation |
| Proteomics | Abundance and modifications of beta-oxidation enzymes | Mitochondrial fraction analysis |
| Live-cell fluorescence imaging | Fatty acid uptake and mitochondrial function | Stress-granule and metabolic coupling studies |
| Seahorse respirometry | Mitochondrial oxygen consumption | Assessing oxidative capacity in knockout cells |
| CRISPR knockout screening | Genes required for fatty acid oxidation | Discovery of novel regulators of GO:0006635 |
| Western blot and immunoprecipitation | Protein levels and interactions of beta-oxidation enzymes | Validating SIRT1/PGC-1alpha/PPARalpha signaling |
Metabolic flux and substrate oxidation assays
Beta-oxidation flux can be measured using radiolabeled or fluorescent fatty acid substrates and by quantifying acylcarnitine species with mass spectrometry. These assays are used to diagnose inherited fatty acid oxidation disorders and to test the effects of genetic perturbations. In cell models, flux measurements provide direct functional readouts of GO:0006635 activity.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can quantify expression of beta-oxidation enzymes and regulators such as PPARA, PPARGC1A, and SIRT1. These methods are used to determine whether genetic or pharmacological interventions reprogram oxidative metabolism. Proteomic analysis of mitochondrial fractions can reveal changes in enzyme abundance and post-translational modifications.
Imaging and mitochondrial function assays
Live-cell imaging with fluorescent fatty acid analogs and mitochondrial membrane potential dyes can assess substrate uptake and mitochondrial function. Stress-granule imaging combined with mitochondrial permeability measurements has been used to show inhibition of fatty acid oxidation. Neuron-astrocyte co-culture imaging can reveal metabolic coupling and protection against fatty acid toxicity.
CRISPR screening and functional genomics
Pooled CRISPR knockout screens can identify genes required for fatty acid oxidation under selective conditions. Candidate hits can be validated with individual knockout or point-mutation models and flux assays. Bioinformatics integration of screen data with metabolic pathways helps prioritize regulators of GO:0006635.
How CRISPR Can Be Used to Study GO:0006635 fatty acid beta-oxidation
Knockout
CRISPR knockout of beta-oxidation genes such as ACADM, CPT2, or HADHA in hepatocyte or myocyte cell lines creates isogenic models to test pathway requirement and metabolic consequences. Knockout of regulators like PPARA or SIRT1 can reveal their contribution to beta-oxidation gene expression. These models are validated by acylcarnitine profiling and flux assays.
Point Mutation
Point-mutation knock-in of patient variants in beta-oxidation genes allows assessment of enzyme function and dominant-negative effects in an isogenic background. This approach is valuable for variants of uncertain significance identified in inherited fatty acid oxidation disorders. Functional readouts include acylcarnitine profiling and substrate oxidation assays.
Knock-in
Knock-in of fluorescent or degron tags at endogenous beta-oxidation loci enables real-time tracking of protein localization and turnover. Reporter knock-ins for PPARA or PPARGC1A can be used to screen for modulators of beta-oxidation gene expression. These models support high-content imaging and biochemical purification.
Overexpression
Overexpression of SIRT1, PGC-1alpha, or PPARalpha in hepatic cells increases beta-oxidation capacity and can rescue lipid accumulation in steatosis models. Overexpression of FABP5 or CD36 can test the impact of substrate delivery on mitochondrial fatty acid oxidation. These gain-of-function models complement knockout studies to establish causality.
How EDITGENE Supports fatty acid beta-oxidation Research
Researchers studying fatty acid beta-oxidation-related genes often need to determine whether a candidate gene is causally involved in pathway flux, substrate handling, or disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations of GO:0006635 components, from single-gene knockouts to library-scale screens, supported by bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for fatty acid beta-oxidation research.
Frequently Asked Questions About fatty acid beta-oxidation
What is fatty acid beta-oxidation (GO:0006635)?
Fatty acid beta-oxidation is the biological process that breaks down fatty acyl chains into acetyl-CoA, NADH, and FADH2, which are used for ATP production.
Where does fatty acid beta-oxidation occur in the cell?
In mammals, the primary site is the mitochondrial matrix, where chain-length-specific enzymes carry out the beta-oxidation spiral.
What genes are involved in fatty acid beta-oxidation?
Key genes include CPT1A, CPT2, SLC25A20, ACADVL, ACADM, ACADS, HADHA, HADHB, ACAA2, PPARA, PPARGC1A, SIRT1, FABP5, and CD36.
How is fatty acid beta-oxidation regulated?
It is regulated by the SIRT1/PGC-1alpha/PPARalpha axis, fatty acid transport proteins such as FABP5 and CD36, and acute stress-responsive mechanisms including stress granules.
What diseases are linked to defects in fatty acid beta-oxidation?
Inherited fatty acid oxidation disorders, MASLD, cardiac disease, and neurodegeneration have been linked to altered beta-oxidation.
What is the role of PPARalpha in fatty acid beta-oxidation?
PPARalpha is a nuclear receptor that drives expression of beta-oxidation genes and is a therapeutic target in steatohepatitis and MASLD.
How can CRISPR be used to study fatty acid beta-oxidation?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models allow causal testing of beta-oxidation genes and regulators in isogenic cell lines.
What methods measure fatty acid beta-oxidation flux?
Acylcarnitine profiling by mass spectrometry, radiolabeled fatty acid oxidation assays, and respirometry are commonly used to measure beta-oxidation flux.
Why is fatty acid beta-oxidation important for the heart?
The heart relies heavily on fatty acid beta-oxidation for ATP production, and its dysregulation contributes to cardiac disease.
Can stress affect fatty acid beta-oxidation?
Yes, stress granules can inhibit fatty acid oxidation by modulating mitochondrial permeability, and neuron-astrocyte coupling protects against fatty acid toxicity.
Conclusion
GO:0006635 fatty acid beta-oxidation is a fundamental energy-producing pathway with essential roles in heart, liver, muscle, and brain metabolism. Its dysfunction underlies inherited metabolic disorders and contributes to MASLD, cardiac disease, and neurodegeneration, making it a high-value target for mechanistic and therapeutic research. CRISPR-based cell models and functional genomics provide powerful tools to dissect the genes and regulatory networks controlling this pathway.
References
- 1. Houten SM et al.. 2016. The Biochemistry and Physiology of Mitochondrial Fatty Acid β-Oxidation and Its Genetic Disorders.. Annu Rev Physiol 78:23-44 PMID: 26474213
- 2. Liao J et al.. 2024. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway.. Phytomedicine 124:155285 PMID: 38185065
- 3. Houten SM et al.. 2010. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation.. J Inherit Metab Dis 33(5):469-77 PMID: 20195903
- 4. Lopaschuk GD et al.. 2010. Myocardial fatty acid metabolism in health and disease.. Physiol Rev 90(1):207-58 PMID: 20086077
- 5. Amen T et al.. 2021. Stress granules inhibit fatty acid oxidation by modulating mitochondrial permeability.. Cell Rep 35(11):109237 PMID: 34133922
- 6. Ioannou MS et al.. 2019. Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced Fatty Acid Toxicity.. Cell 177(6):1522-1535.e14 PMID: 31130380
- 7. Yu YY et al.. 2025. Asprosin-FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development.. Adv Sci (Weinh) 12(21):e2415846 PMID: 40231957
- 8. Samovski D et al.. 2023. Fatty Acid Transport and Signaling: Mechanisms and Physiological Implications.. Annu Rev Physiol 85:317-337 PMID: 36347219
